Inclusion Criteria:

1. Men or women aged <65 years.

2. Previously untreated subjects with multiple myeloma.

3. No clinically significant cardiac amyloidosis (Echocardiography septal≤10mm, brain
natriuretic peptide (BNP) < 500).

4. Pulmonary infection (if any) must be controlled effectively.

5. Chronic viral hepatitis (if any) must be controlled effectively.(Subjects with HBs Ag
positive need to monitor hepatitis B virus-DNA (HBV-DNA )quantitative test
regularly）；

6. Liver function (aminotransferase, bilirubin）?2 x the upper limit of normal (ULN).

7. Expected lifetime More than 3 months.

8. Be able to read and sign (or their legally-acceptable representatives must sign) an
informed consent document indicating that they understand the purpose of and
procedures required for the study and are willing to participate in the study.

Exclusion Criteria:

1. Patients with relapsed multiple myeloma.

2. Need to change the program according to the researchers' evaluated patients with
disease progression during treatment.

3. Had uncontrolled or severe cardiovascular disease. Had a myocardial infarction within
6 months of enrolment, New York Heart Association (NYHA) Class III or IV heart
failure, uncontrolled angina, clinically significant pericardial disease, or cardiac
amyloidosis.

4. Has a history of allergic reaction to compounds containing boron or mannitol.

5. Severe neuropathy may affect the treatment, according to the researchers to
determine.

6. According to the program or the investigator's judgment, the patient is suffering
from a serious physical illness or mental illness may interfere with participation in
this clinical study.

7. Concurrent treatment with another investigational agent.

8. Pregnant or breast-feeding women.